RESUMO
We report two cases of fulminant type 1 diabetes in previously well migrants from South East Asia. This entity, which is rare outside East or South-East Asia, has a high perinatal mortality. The clinical presentation differs markedly from that of typical newly recognised type 1 diabetes in pregnancy. In both our cases, the neonates required intensive care but survived.
Assuntos
Diabetes Mellitus Tipo 1/complicações , Diabetes Mellitus Tipo 1/diagnóstico , Diabetes Gestacional/diagnóstico , Cetoacidose Diabética/diagnóstico , Adulto , Cetoacidose Diabética/terapia , Emigrantes e Imigrantes , Feminino , Teste de Tolerância a Glucose , Hemoglobinas Glicadas/análise , Humanos , Recém-Nascido , Terapia Intensiva Neonatal , GravidezRESUMO
AIMS: To examine whether women with an HbA1c of 41-49 mmol/mol (5.9-6.6%) at diagnosis of gestational diabetes are higher risk than women with an HbA1c of < 41 mmol/mol (5.9%) and whether pregnancy outcomes are improved if treated at < 24 weeks' gestation. METHODS: This was an observational study of women with gestational diabetes diagnosed by early HbA1c screening or subsequent oral glucose tolerance test at < 34 weeks' gestation who delivered at National Women's Health, Auckland, from July 2012 to June 2014. Data were extracted from the hospital database. Women with HbA1c 41-49 mmol/mol (5.9-6.6%) were divided into those seen < 24 weeks (Early, n = 134) and those seen ≥ 24 weeks (Later, n = 151). Those with HbA1c < 41 mmol/mol (5.9%) were labelled Other GDM (n = 661). RESULTS: The Early and Later groups, compared with Other GDM, had more Polynesian and fewer (non-Indian) Asian women, higher BMI and more required medication (P < 0.001). More were smokers (P = 0.007, 0.02) and more had chronic hypertension (P < 0.001, 0.02). There were higher rates of adverse outcomes in the Later group than the Other GDM group (pre-eclampsia 8.0% vs. 2.4%, P = 0.001, preterm birth 16.6% vs. 8.2%, P = 0.002, neonatal admission 15.5% vs. 9.2%, P = 0.02). Outcomes were similar between the Early group and Other GDM group (pre-eclampsia 1.5% vs. 2.4%, P = 0.5, preterm birth 10.5% vs. 8.2% P = 0.4, neonatal admission 13.6% vs. 9.2%, P = 0.12). Comparing the Early and Later groups, the Early group had less pre-eclampsia, 1.5% vs. 8.0%, adjusted P = 0.03. Other outcomes were not statistically different. CONCLUSIONS: An HbA1c of 41-49 mmol/mol (5.9-6.7%) identifies a higher-risk group of women with gestational diabetes. Overall, our data support early treatment of women with an HbA1c ≥ 41 mmol/mol (5.9%).
Assuntos
Diabetes Gestacional/diagnóstico , Hemoglobinas Glicadas/análise , Doenças do Recém-Nascido/prevenção & controle , Pré-Eclâmpsia/prevenção & controle , Gravidez de Alto Risco/sangue , Nascimento Prematuro/prevenção & controle , Adulto , Povo Asiático , Diabetes Gestacional/sangue , Diabetes Gestacional/etnologia , Diabetes Gestacional/fisiopatologia , Diabetes Gestacional/terapia , Diagnóstico Precoce , Feminino , Humanos , Recém-Nascido , Doenças do Recém-Nascido/epidemiologia , Doenças do Recém-Nascido/etnologia , Doenças do Recém-Nascido/etiologia , Terapia Intensiva Neonatal , Masculino , Havaiano Nativo ou Outro Ilhéu do Pacífico , Nova Zelândia/epidemiologia , Pré-Eclâmpsia/epidemiologia , Pré-Eclâmpsia/etnologia , Pré-Eclâmpsia/etiologia , Gravidez , Segundo Trimestre da Gravidez , Gravidez de Alto Risco/etnologia , Nascimento Prematuro/epidemiologia , Nascimento Prematuro/etiologia , Nascimento Prematuro/terapia , Diagnóstico Pré-Natal , Fatores de Risco , População BrancaRESUMO
AIM: The aim of the study is to compare the effects of metformin and insulin treatment for gestational diabetes mellitus (GDM) on vitamin B12 and homocysteine (Hcy) status. METHODS: Women with GDM, who met criteria for insulin treatment, were randomly assigned to metformin (n = 89) or insulin (n = 91) in the Adelaide cohort of the metformin in gestational diabetes (MiG) trial. Fasting serum total vitamin B12 (TB12), holotranscobalamin (HoloTC), a marker of functional B12 status and plasma Hcy concentrations were measured at 20-34 weeks (at randomization) and 36 weeks gestation, then at 6-8 weeks postpartum. RESULTS: Circulating TB12, HoloTC and Hcy were similar in both treatment groups at each time point. Women who were taking dietary folate supplements at randomization had higher serum TB12 and HoloTC at randomization than those not taking folate. Overall, serum TB12 fell more between randomization and 36 weeks gestation in the metformin group than in the insulin group (metformin: -19.7 ± 4.7 pmol/l, insulin: -6.4 ± 3.6 pmol/l, p = 0.004). The decrease in serum TB12 during treatment was greater with increasing treatment duration in metformin-treated (p < 0.001), but not in insulin-treated women. CONCLUSIONS: Total, but not bioavailable, vitamin B12 stores were depleted during pregnancy to a greater extent in metformin-treated than in insulin-treated women with GDM, but neither analyte differed between groups at any stage. This adds further evidence supporting metformin as a safe alternative treatment to insulin in GDM. Further investigation is needed to evaluate whether women treated with metformin for longer periods in pregnancy require additional B12 or other supplementation.
Assuntos
Diabetes Gestacional/tratamento farmacológico , Hiper-Homocisteinemia/induzido quimicamente , Hipoglicemiantes/efeitos adversos , Insulina/efeitos adversos , Metformina/efeitos adversos , Estado Nutricional/efeitos dos fármacos , Deficiência de Vitamina B 12/induzido quimicamente , Adulto , Biomarcadores/sangue , Estudos de Coortes , Diabetes Gestacional/sangue , Feminino , Homocisteína/sangue , Humanos , Hipoglicemiantes/uso terapêutico , Insulina/uso terapêutico , Metformina/uso terapêutico , Período Pós-Parto , Gravidez , Complicações na Gravidez/induzido quimicamente , Segundo Trimestre da Gravidez , Terceiro Trimestre da Gravidez , Austrália do Sul , Transcobalaminas/análise , Vitamina B 12/sangueRESUMO
AIMS: To review pregnancy outcomes in women with Type 2 diabetes (Type 2 DM), comparing women treated with those not treated with metformin. METHODS: Data were collected by case-note review for all pregnancies in women with Type 2 DM over a 6-year period (1998-2003) at the National Women's Hospital. Two hundred and fourteen pregnancies were included, metformin was taken in 93 pregnancies and continued until delivery in 32; the remaining 121 pregnancies comprised the control group. The principal outcome measures were preeclampsia, perinatal loss and neonatal morbidity. RESULTS: Baseline characteristics differed between groups: women in the metformin group had greater mean (SD) body mass index [35.5(7.6) vs. 33.5(6.6) kg/m2, P < 0.05], more chronic hypertension (19% vs. 7%, P < 0.05) and higher mean (SD) first trimester glycated haemoglobin (HbA1c) levels [8.3(1.9)% vs. 7.5(1.7)%, P < 0.005]. There was no difference between metformin and control groups, respectively, in the rate of preeclampsia (13% vs. 14%, P = 0.84), perinatal loss (3% vs. 2%, P = 0.65) or neonatal morbidity, including rate of prematurity (23% vs. 22%, P = 0.7), admission to the neonatal unit (40% vs. 48%, P = 0.27), respiratory distress (9% vs. 18%, P = 0.07) and treatment with intravenous dextrose (20% vs. 31%, P = 0.08). CONCLUSIONS: Pregnant women with Type 2 DM who were treated with metformin had more risk factors for adverse pregnancy outcomes, but no differences in outcomes were seen compared with women not taking metformin. We need randomized trials to address potential benefits of metformin treatment in this population that may be masked by current practice.
Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Hipoglicemiantes/uso terapêutico , Metformina/uso terapêutico , Gravidez em Diabéticas/tratamento farmacológico , Adulto , Índice de Massa Corporal , Doença Crônica , Parto Obstétrico , Diabetes Mellitus Tipo 2/epidemiologia , Feminino , Mortalidade Fetal , Hemoglobinas Glicadas/análise , Humanos , Hipertensão/epidemiologia , Recém-Nascido , Doenças do Recém-Nascido/epidemiologia , Auditoria Médica , Nova Zelândia/epidemiologia , Pré-Eclâmpsia/epidemiologia , Gravidez , Complicações Cardiovasculares na Gravidez/epidemiologia , Resultado da Gravidez/epidemiologia , Gravidez em Diabéticas/epidemiologiaRESUMO
OBJECTIVE: This prospective audit reports pregnancy outcomes, anticoagulation complications, and anti-Xa levels in women with mechanical heart valves who were treated with therapeutic enoxaparin plus aspirin during pregnancy. STUDY DESIGN: Between 1997 and 1999, 11 women with mechanical heart valves were treated with enoxaparin, 1 mg/kg twice daily, and aspirin, 100 to 150 mg daily during 14 pregnancies. Predose and 4-hour postdose anti-Xa levels were monitored monthly. RESULTS: There were 9 live births, 3 miscarriages, and 2 terminations. In 48 months of enoxaparin treatment, one woman who had a documented valve thrombosis when she presented at 8 weeks' gestation also had a valve thrombosis at 20 weeks' gestation. There were no enoxaparin-related hemorrhagic complications. Mean (SD) anti-Xa levels were 0.46 (0.12) U/mL predose and 0.89 (0.22) U/mL 4 hours postdose. CONCLUSION: Successful pregnancy outcome may be achieved with therapeutic subcutaneous enoxaparin, but its efficacy at preventing valve thrombosis remains uncertain. Further data are required before use of enoxaparin during pregnancy in women with mechanical heart valves can be recommended.
Assuntos
Anticoagulantes/uso terapêutico , Enoxaparina/uso terapêutico , Próteses Valvulares Cardíacas , Complicações Cardiovasculares na Gravidez/prevenção & controle , Adulto , Anticorpos/análise , Aspirina/uso terapêutico , Fator Xa/imunologia , Feminino , Doenças das Valvas Cardíacas/prevenção & controle , Humanos , Gravidez , Complicações Cardiovasculares na Gravidez/tratamento farmacológico , Resultado da Gravidez , Estudos Prospectivos , Trombose/prevenção & controleRESUMO
A case of necrotizing fasciitis in a healthy woman taking a nonsteroidal antiinflammatory drug in the puerperium is presented. The role of increased virulence of group A streptococci and the association of necrotizing fasciitis with nonsteroidal antiinflammatory drugs is reviewed.